USO 25031
AMG 757: 20240178 A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
Disease Types: Lung Cancer Research
Eligibility Requirements:
• Histologically/cytologically documented ES-SCLC
• Mixed histology tumors with predominant SCLC histology are eligible
• No prior tx for SCLC
• Curative intent tx for LS-SCLC are eligible if ≥6 months had elapsed from
end of all tx and PD
• Eligible to receive carboplatin, etoposide and durvalumab as 1L tx
• Measurable disease as defined per RECIST 1.1
• Tumor tissue must be submitted if sample is available
• Symptomatic CNS metastases or leptomeningeal disease are excluded
• Untreated AND asymptomatic brain metastases that don’t require
corticosteroids, nor local therapy are eligible
• Treated brain metastases are eligible if radiation tx was completed at least 2
weeks prior to C1D1
• Pt must be clinically stable and on stable/decreasing doses of steroid (≤ 10 mg)
prior to C1D1
• Has/is planning to receive consolidative chest radiation for ES-SCLC
excluded
• Prior tarlatamab or any selective inhibitor of the DLL3 pathway tx are
excluded
For more information on this trial CLICK HERE .
Available at: